Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BT02 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| dose escalation and expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BT02 | DRUG | monoclonal antibody injection with intravenous administration every 2 or 3 weeks |
Inclusion Criteria: 1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy . 2. Adequate organ and hematologic function. 3. At least 1 extracrani...
Top 20 of 51 competitors
BT02 is an investigational small molecule being developed for the treatment of advanced melanoma. It is currently in Phase 1 clinical development, with a study targeting patients with advanced malignant melanoma and advanced solid tumors. The drug is not yet approved and remains in clinical trials.
BT02 is being developed by cbdMD, Inc., a company traded under the ticker YCBD. The company is conducting a Phase 1 clinical trial of BT02 for advanced melanoma. As of the latest information, the drug is in early-stage clinical development and has not received regulatory approval.
BT02 is in Phase 1 clinical development. It is being studied in an open-label, uncontrolled trial for patients with advanced melanoma and advanced solid tumors. The drug is investigational and has not been approved by regulatory authorities. The Phase 1 trial is not yet recruiting participants.
BT02 is being evaluated in a Phase 1 clinical trial with the identifier NCT07107178. This study, titled "A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma," is designed to enroll 58 participants aged 18 years and older. The trial is not yet recruiting and is uncontrolled.
BT02 is a small molecule therapeutic being developed for oncology indications. Its specific molecular target has not been disclosed in available information. The drug is currently in Phase 1 clinical trials for advanced melanoma, where its safety and preliminary efficacy are being evaluated.